{"filings":[{"id":779356,"accession_number":"0001534969-26-000028","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-06-01T20:44:21+00:00","items":["5.02","9.01"],"status":"ready","headline":"Sera Prognostics director Jeff Elliott resigns ahead of annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Elliott notified Board of resignation effective June 4, 2026; not due to any disagreement.","Elliott's term was expiring at Annual Meeting; he was not a nominee for re-election.","Board reduced size to seven directors following resignation.","Company in advanced discussions with candidates to fill vacancy; expects near-term appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93508,"accession_number":"0001534969-26-000024","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.","PRIME trial (5,018 women) showed PreTRM test cut early preterm births 56% (<32 wks) and 32% (<35 wks); NICU admissions down 20%.","Cash and securities $86.8M; cash runway extended through 2029 via cost restructuring.","Launched third physician partnership; active payer discussions with 13 payers across 15 states.","CE marking submission for Europe on track for mid-2026; expanding European evidence base."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":14000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105196,"accession_number":"0001534969-26-000008","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.","Revenue minimal: $10k Q4, $81k full year; company remains pre-commercial.","Cash $95.8M at Dec 31, 2025; expects to fund operations through 2028.","PRIME study published Jan 2026: PreTRM test reduced preterm births <32 wks by 56%, NICU admissions by 20%.","Completed $57.5M follow-on offering Feb 2025; added CMO Dr. Inglis, CCO Anderson in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105195,"accession_number":"0001193125-26-007850","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics posts investor presentation; no material updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on Jan 8, 2026; only title slide 'Redefining pregnancy care to reduce preterm birth' available.","No financial results, revised guidance, or new business milestones included in the filing.","Presentation appears to be a routine update with no substantive new information.","Company trades as SERA on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105194,"accession_number":"0001193125-26-005531","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PRIME study: PreTRM blood test cuts preterm births <32 wks by 56%, NICU admissions by 20%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Randomized trial of 5,018 women: 56% fewer births <32 wks, 32% fewer <35 wks.","20% reduction in NICU admissions and neonatal morbidity odds.","One NICU day saved per 4.2 patients screened; number needed to screen for NICU admission: 39.","Study published in Pregnancy journal (Society for Maternal-Fetal Medicine).","Jefferies fireside chat on Jan 9, 2026 at 8:30 am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121449,"accession_number":"0001193125-25-292074","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics announces PRIME preterm-birth study accepted for peer-reviewed publication","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PRIME study findings accepted for publication, following late-breaking abstract at SMFM annual meeting in 2025.","Study is one of the largest on preterm birth evaluating risk assessment plus clinical interventions.","Company expects to share manuscript data at medical meetings and with research analysts.","No financial terms or specific study results disclosed in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121448,"accession_number":"0001193125-25-280167","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Q3 revenue $16k, net loss $7.8M; launches Medicaid pilot in Nevada","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16k vs $29k YoY; net loss $7.8M vs $7.9M; cash $102.4M funds operations through 2028.","Inaugural Medicaid pilot launched in Nevada; payer discussions across 13 states covering 33% of U.S. births.","PRIME study full results on track for publication in 2025; health economic data also forthcoming.","Appointed Dr. Tiffany Inglis as CMO and Marisol Urbano as Head of Commercial Operations.","SG&A rose to $5.7M from $5.4M due to commercial investments; R&D fell to $3.3M as PRIME study concluded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":71000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138116,"accession_number":"0001534969-25-000005","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics posts investor presentation at H.C. Wainwright conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["New investor presentation posted to corporate website on September 5, 2025.","Presented at H.C. Wainwright 27th Annual Global Investment Conference same day.","No specific financial or clinical data disclosed in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138115,"accession_number":"0000950170-25-103994","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q2 revenue $17K, net loss $8.0M, PreTRM progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17,000 vs $24,000 in Q2 2024; net loss $8.0M vs $8.3M.","Operating expenses $9.3M flat; R&D down 24% to $3.3M; SG&A up to $6.0M.","Cash $108.5M as of June 30, 2025, expected to fund through 2028.","PRIME study full results on track for publication this year; commercial traction with Medicaid plans.","Appointed Lee Anderson as CCO, Chuck Hyde as Head of Market Access, Jennifer Zibuda as Head of IR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":55000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155540,"accession_number":"0000950170-25-082539","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sera Prognostics announces annual meeting results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. elected as Class I directors for three-year terms.","Auditor Ernst & Young ratified for FY2025 with 24,311,571 votes for, 2,691 against.","Quorum of 66.2% of eligible shares (24,314,265 of 36,701,381) present at June 5, 2025 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155539,"accession_number":"0000950170-25-067231","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics appoints Lee Anderson as Chief Commercial Officer; 30-year diagnostics veteran to lead PreTRM rollout","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lee Anderson appointed CCO effective May 8, 2025; reports to CEO Zhenya Lindgardt.","Anderson previously led US Oncology Sales at Genomic Health (acquired by Exact Sciences) and was CCO at Biofidelity.","He will drive commercial adoption of the PreTRM test following positive PRIME study results.","Company is in commercial phase; Anderson brings over 30 years of healthcare sales and marketing leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155538,"accession_number":"0000950170-25-065654","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q1 revenue $38k, net loss $8.2M; payor discussions advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $38k vs nil in prior year; net loss $8.2M vs $8.1M.","Cash and securities $114.2M as of March 31, 2025.","R&D expenses down 9% to $3.3M; SG&A up to $5.9M.","PRIME study met primary success criteria; engaging payors and planning Medicaid pilots.","Appointed Jeff Elliott to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":38000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174031,"accession_number":"0000950170-25-042005","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.","PRIME study: 25% reduction in neonatal morbidity/mortality index and 18% reduction in length of stay in modified ITT.","Full year 2024 revenue $77,000; net loss $32.9M vs $36.2M in 2023.","Raised $57.5M in Feb 2025 public offering; cash runway extended through 2028.","R&D expenses $3.1M in Q4, down 19% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174030,"accession_number":"0001193125-25-024518","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Sera Prognostics prices $50M public offering of 1.25M shares and 11.25M pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering priced at $4.00 per share of Class A common stock and $3.9999 per pre-funded warrant.","Gross proceeds expected to be ~$50M before underwriting discounts and commissions.","Underwriters have 30-day option to purchase up to an additional 1.875M shares.","Proceeds to expand US commercial infrastructure, accelerate EU expansion, fund PreTRM studies and potential FDA submission.","Existing cash plus net proceeds expected to fund operations through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174029,"accession_number":"0001193125-25-023577","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sera Prognostics terminates unused $50M ATM offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No shares of Class A common stock were sold under the ATM offering since its August 2024 inception.","Sales agreement with TD Cowen remains in force; no new sales without a fresh prospectus supplement.","Termination of the ATM prospectus supplement effective February 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174028,"accession_number":"0001193125-25-018170","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).","PRIME study met both co-primary endpoints: 25% reduction in neonatal morbidity (NMI) and 18% reduction in neonatal length of stay in mITT population.","ITT analysis: 20% reduction in NMI, 8% reduction in neonatal stay, and 20% reduction in NICU admissions.","PreTRM test classified 23.5% as higher risk; number needed to screen 3-4 to save one NICU day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174027,"accession_number":"0000950170-25-004909","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sera Prognostics files 8-K for new investor presentation at J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated investor presentation to its website on January 13, 2025.","Presentation to be shared at 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025 at 9:45 a.m. PT.","Exhibit 99.1 investor presentation filed but specific content not provided in filing text.","No financial or operational updates disclosed in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174026,"accession_number":"0000950170-25-003021","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sera Prognostics PRIME study topline results published by SMFM","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["SMFM published an abstract of topline results for the PRIME study on preterm birth risk assessment.","Full results to be presented at SMFM 2025 Pregnancy Meeting on January 31, 2025.","Company to host conference call on February 6, 2025 at 12 p.m. ET to discuss results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190986,"accession_number":"0000950170-24-122288","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q3 revenue $29k, net loss $7.9M; PRIME study data locked","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell to $29k from $42k YoY; net loss widened to $7.9M from $7.2M.","Operating expenses $8.9M, up 8% YoY; SG&A $5.4M due to growth investments.","PRIME study database locked in Sept; results planned for 2025 conferences and journal submission.","Direct-to-consumer PreTRM testing via website launched Oct 1; TV awareness campaign with Dennis Quaid and Meg Ryan.","Ambient whole blood collection lowers cost of goods and boosts lab capacity for scalability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":53000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207455,"accession_number":"0001534969-24-000151","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sera Prognostics Q2 2024 net loss narrows to $8.3M; revenue drops to $24k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue was $24,000, down from $123,000 in Q2 2023.","Net loss improved 21% to $8.3M from $10.5M in Q2 2023.","Operating expenses decreased 20% to $9.3M; SG&A down 38% to $4.9M, R&D up 19% to $4.4M.","Published positive AVERT PRETERM TRIAL results; PRIME study database lock expected mid-September; NY State conditional approval for whole-blood collection."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":24000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224880,"accession_number":"0001534969-24-000122","cik":1534969,"company_name":"SERA PROGNOSTICS, INC.","ticker":"SERA","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sera Prognostics annual meeting elects directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 20,402,055 shares (64.4% of eligible) present at June 6, 2024 annual meeting.","Elected Critchfield (11.38M for), Lindgardt (9.38M for), Phillips (11.49M for) as Class III directors.","Ratified Ernst & Young as auditor for FY2024 with 20,391,485 votes for, 226 against, 10,344 abstain.","8,396,389 broker non-votes on director elections; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":80275383.67579907,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}